New drug combo aims to shrink tough lung cancers
NCT ID NCT05949606
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental drugs, SI-B001 and SI-B003, given together with or without chemotherapy in 160 people with advanced non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the combination shrinks tumors. Participants must have tried other treatments or have limited options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SI-B001 and SI-B003 (two experimental drugs given by IV infusion, sometimes with chemotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with advanced non-small cell lung cancer that has not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drugs may not prove effective or safe enough for wider use. Side effects from the combination are not yet fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact